Immunological biomarker analyses, including YF plaque-reduction neutralization test (PRNT) and YF phenotypic and functional biomarkers, were performed for each participant This study was approved by the Ethics Committee for studies with human subjects at Instituto Ren Rachou FIOCRUZ (CPqRR # 180911)

Immunological biomarker analyses, including YF plaque-reduction neutralization test (PRNT) and YF phenotypic and functional biomarkers, were performed for each participant This study was approved by the Ethics Committee for studies with human subjects at Instituto Ren Rachou FIOCRUZ (CPqRR # 180911). The data demonstrated that csDMARD Gap 26 therapy did not affect the duration of protective immunity induced by the 17DD-YF vaccine compared to that of CONT, as both presented a significant time-dependent decline at 10 years after vaccination. Conversely, cs+bDMARD therapy induced a premature depletion in the main determinants of the vaccine protective response, with diminished PRNT seropositivity levels between 5 and 9 years and impaired effector Gap 26 memory in CD8+T cells as early as 15 years after 17DD-YF vaccination. == Conclusions == These findings could support changing the vaccination schedule of Gap 26 this population, with the possibility of a planned booster dose upon the suspension of bDMARD in cases where this is allowed, even before 10 years following 17DD-YF vaccination. The benefit of a planned booster dose should be evaluated in further studies. == Trial registration == RBR-946bv5. Date of registration: March 05, 2018. Retrospectively registered Keywords:Immunomodulatory therapy, Yellow fever vaccine, Neutralizing antibodies, Cellular immunity, Rheumatoid arthritis == Background == Rheumatoid arthritis (RA) is one of the most prevalent chronic autoimmune diseases, and it mainly affects the peripheral joints and promotes synovitis, which may lead to cartilage damage and bone erosion [1]. The prevalence of RA ranges from 0.40 to 1 1.60% and 0.46 to 1 1.00% in Latin America [2,3] and Brazil [4,5], respectively. In recent decades, significant advances in RA clinical and therapeutic approaches have been reported worldwide, encompassing the use of conventional synthetic and biological strategies, such as pathway inhibitors/antagonists. While effective for controlling RA activity, these immunomodulatory therapies may affect pre-existing immunity to infectious diseases. In a scenario in which immunizations Gap 26 are effective to elicit protective immunity, it becomes relevant to understand the impact that disease-modifying anti-rheumatic drugs (DMARD) has on correlates of protection acquired upon vaccination [6,7]. The ability of DMARD to modify or affect pre-existing vaccine-induced protective immunity, including the function of memory T and B cells and, as a consequence, yellow fever (YF)-specific neutralizing antibody levels, has already been reported [8]. There is a paucity of data available regarding the impact of DMARD on the duration of YF vaccine-induced immunological memory developed by RA patients. The recent YF outbreaks in Angola (2016) and Brazil (2017/2018) [9,10] brought about a relevant question regarding the impact that DMARD may have on RA patients previously immunized with the 17DD-YF vaccine. Assessing the duration of the immune responses triggered by YF vaccines can provide insights into elucidating the vulnerability to YF infection of RA patients under DMARD therapy. In this context, the aim of the present study was to verify whether conventional synthetic or biological DMARD impact the cellular and humoral immunological memory of RA Gap 26 patients previously immunized with the 17DD-YF vaccine. These findings may be useful when making clinical decisions regarding YF vaccination in RA patients. == Methods == == Subjects == Between September 17, 2014, and December 06, 2016, 136 adult patients ( 18 years) who met Rabbit Polyclonal to CDC25C (phospho-Ser198) ACR classification criteria for RA were enrolled in this open-label, parallel cohort, single-center study. Patients had received a single dose of the 17DD-YF vaccine and time after vaccination estimated according to their vaccination card records; some patients have been inadvertently vaccinated before starting the DMARD therapy; all patients were residents of the metropolitan area of Brasilia, DF, Brazil, and received medical care at the University Hospital of Brasilia, University of Brasilia. Fifteen patients were excluded due to their 17DD-YF vaccination records showing < 1 year, > 30 years (n= 12), or missing data (n= 3). The final.